//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
Profile
Loading...
Group leader Research Institute of Molecular Pathology (IMP) impvienna.bsky.social in Vienna, trained at MSKCC, working on #cancer #tumorimmunology #resistance. Mentor. Mum. Views are my own. https://www.obenauflab.com/ https://www.imp.ac.at/
Anna Obenauf









Loading...
#Agenda Via @obenaufa.bsky.social @fusionconf.bsky.social
Three more days to apply for the *Swiss Bridge Award*! This time focusing on Tumor Heterogeneity. It truly is a wonderful grant opportunity with maximum flexibility for an innovative project. www.swissbridge.ch/call-for-app...
2mo
1mo
Really exciting lineup of speakers in a beautiful venue. I really look forward to it! #cancerimmunology
Amazing talk by @johannajoyce.bsky.social at #THPT25 โ€” an impressive tour de force, beautifully contextualizing two decades of work. ๐Ÿ˜
Coming originally from cancer biology and only more recently working in tumor immunology, this award means even more to me. Thank you for the trust and for so warmly welcoming me into the community.
Thrilled and honored to be awarded the 2025 EJI Ita Askonas Prize by @efis-immunology.bsky.social ! ๐ŸŽ‰ So grateful to the committee and especially to my incredible team and collaborators โ€” this wouldnโ€™t be possible without you! www.efis.org/news/2025-ej...
Beautiful talk by @obenaufa.bsky.social at #THPT25 โ€” first walking us through the key conclusions of her latest Nature paper, then offering a glimpse into the next chapter of her work unravelling the mysteries of drug tolerant persistent cells. Looking forward to see where this story goes next!
6mo
6mo
5mo
Anna Obenauf
5mo
6mo
๐ŸŽ‰ Congratulations to our Anna Obenauf, IMP Senior Group Leader, who has been elected as a Corresponding Member of the Austrian Academy of Sciences, for her outstanding contributions to cancer research: https://www.imp.ac.at/news/article/anna-obenauf-elected-to-the-austrian-academy-of-sciences
#CancerImmuno Early Bird & Talk Submission Deadline closing this week!!! ๐Ÿšจ Click here to register now: bit.ly/4sGvk8E #FusionImmunology #FusionCancerResearch
๐Ÿ“ขWant to speak at the #CancerImmuno conference? Good news! The chairs have released additional short talk slots and extended the submission deadline to 26 February 2026! Submit your abstract for a chance to present your work alongside leading researchers in the field. ๐Ÿ‘‰ Register now: bit.ly/3NRB7Iu
2mo
5mo
4mo
Anna Obenauf
Anna Obenauf
Anna Obenauf
Anna Obenauf
Laoui Team @ VIB-VUB
Fusion Conferences
Fusion Conferences
IMP
www.swissbridge.ch
Call for application - SwissBridge